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Drug biotransformation studies appear as an alternative to pharmacological studies of metabolites, development of new drug 
candidates with reduced investment as well as the most efficient production of chemical structures involves and drug quality control 
studies. A wide range of reactions in biotransformations process are catalyzed by microorganisms. Fungi can be considered as a 
promising source of new biotransformation reactions. The aim of this study was to evaluate the capacity of metronidazole 
biotransformation through the filamentous fungus Cunninghamella elegans ATCC 9245. The monitoring of metabolite formation 
was performed by high-performance liquid chromatography (HPLC) coupled to ultraviolet (UV) spectrophotometry. The results of 
the biotransformation of metronidazole showed drug consumption in culture and formation of four new chromatographic peaks of 
chemical structures not elucidated. The method showed it became linear over 10-70 μg/mL (r = 0.999953). Accuracy, precision and 
stability studies agree with international guidelines.  Results are consistent in accordance to the principles of green chemistry as the 
experimental conditions had a low environmental impact, and little use of environmental harmful solvents. 
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Introduction  
 
Drug biotransformation is considered as a detoxification 
process leads to the formation of polar substances or a form 
easily excreted from the organism. The understanding of drug 
metabolism plays an important role in the development of 
new drugs and pharmacological and toxicological studies (1).  
Biotransformation is an alternative tool with great potential, 
especially for the development of sustainable technologies to 
produce chemicals and drugs, that is, green chemistry. 
Microbial biotransformations have been extensively 
employed in the drug discovery and development mainly due 
to their ability to produce enantioselective products. In 
addition to that, biotransformation provides an efficient and 
environmentally friend way to produce large-scale 
metabolites of drugs and is considered an alternative 
approach to the asymmetric synthesis and conventional in 
vivo and in vitro metabolism studies (2–4). This kind of 
process is attractive for the synthesis of new drug metabolites, 
which are required for biological and toxicity tests as 
analytical standards (5–7). Many mammalian phases I 
metabolic reactions and phase II metabolic reactions, 
including hydroxylation, oxygen and nitrogen dealkylation, 
dehydrogenation, and glucuronide and sulfate conjugation, 
also occur in microbial models.  
The filamentous fungi Cunninghamella elegans is useful 
biocatalysts to modify functional groups, including 
hydroxylation of aromatic rings, reduction of ketones, 
oxidations, and demethylations (8–11). Cunninghamella 
species can metabolize a wide variety of xenobiotics using 
both phases I and phase II reactions, oftentimes giving rise 
new compounds (7,12,13). 
Several studies have examined biotransformations of drugs 
by fungi, such as C. elegans, demonstrating a broader 
application to produce drugs metabolites and guiding drug 
development. Besides that, fungi have not been investigated 
for possible biotransformation of metronidazole, an anti-
helminthic drug. Metronidazole (MTZ) is a nitroimidazole 
antibiotic family and it is widely used in the therapy of several 
diseases, such as trichomoniasis, amoebiasis and anaerobic 
infections. The drug is one of the most important agents 
combined with others antimicrobial therapies used to 
eradicated Helicobacter pylori, the main cause of gastritis and 
duodenal ulcers. Studies of metronidazole metabolism in 
humans have shown the drug is intensively metabolized by 
the hepatic microsomal cytochrome P450 with subsequent 
renal elimination (14). The metabolism of metronidazole is 
well established in humans (15). However, MTZ-metabolites 
produced by filamentous fungi are still unknown. The human 
biotransformation of metronidazole produces three 
metabolites.  The 2-hydroximetronidazole results from the 
hydroxylation of 2-methyl group, 1-metronidazole acetic 
acid, from the oxidation of the 1-ethyl group, and glucuronide 
conjugation on the 1-ethyl group (Figure 1). Both metabolites 
are found in the urine. Metronidazole and 2-
hydroximetronidazole had been shown in vitro activity 
against anaerobic bacteria (16).  
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Figure 1 Metronidazole and major metabolites in human urine. 
Until now, there have been no reports in the literature of 
metabolism studies performed with MTZ (1,12). In the light 
of above considerations, the purpose of this study was first 
elaborate knowledge of the biotransformation potential of C. 
elegans ATCC 9245 for MTZ and secondly to develop and 
validate method using HPLC for MTZ analysis in liquid 
culture medium.  
Material and methods 
Chemicals 
Methanol and acetonitrile of HPLC grade were purchased 
from Merck (New Jersey, USA) and Vetec (São Paulo, 
Brazil), respectively. Czapek broth was obtained from Kasvi 
(Paraná, Brazil) and Sabouraud dextrose agar (HiMedia, 
Mumbai, India). Water was purified by a Milli-Q system 
Millipore (Molsheim, France). Metronidazole was obtained 
from Farmanguinhos, FIOCRUZ (99.9%). 
Dimethylsulfoxide bought from Labsynth (Diadema, São 
Paulo). 
Fungal biotransformation protocol 
C. elegans ATCC 9245 was donated by the Bioconversion 
Laboratory, Universidade Federal de Goiás (Goiânia, Goiás, 
Brazil). Stock cultures were cut in discs of 0.5 cm in diameter 
of Sabouraud-dextrose agar and maintained on sterile sodium 
chloride 0.9% (w/v) at 5 °C.  
Biotransformation  
The biotransformation assay was divided in three stages.  The 
stage I initiated from a standard spore solution of C. elegans. 
It was prepared by growing the fungi for 3 days at 27 ºC in 
tubes containing Sabouraud-dextrose agar. A spore 
suspension was prepared, and 108 spores of strain were 
inoculated in a 250 mL (17) Erlenmeyer vial containing 150 
mL of a liquid medium with and cultivated for 48 hours at 27 
°C in an orbital shaker (New Brunswick™ Innova® 2300) at 
120 rpm.  
Stage II was initiated 2 days after inoculation. The substrate 
MTZ (10.5 mg), which was previously solved in 
dimethylsulfoxide: water (1:1, v/v) was added into each vial 
containing Czapek broth (drug control, DC) and Czapek broth 
with spores of C. elegans (biotransformation flask, BIO) to 
give the final MTZ concentration of 70 μg/mL. Control 
samples consisted of sterile culture broth Czapek (blank: B), 
and culture medium in the presence of fungi (growth control: 
GC). Both substrate and organism controls were treated under 
same conditions of incubation. 
In stage III, every 24 hours after MTZ addition, 2 mL aliquot 
of the liquid culture medium was collected in triplicate (under 
aseptic conditions). The samples were filtered through nylon 
membrane (0.45 μm, Whatman®) and stored at low 
temperature (- 20°C) until the analysis day (8th day).  
Chromatographic conditions and apparatus 
Liquid chromatographic analyses of samples were conducted 
on a Shimadzu LC-10A system equipped with a LC-20AT 
pump, SPD-20AV UV-VIS variable wavelength detector 
(313 nm), DGU- 20A5 degasser, CBM-20A controller 
system, and SIL-20A injection valve with 20 μL loop (Kyoto, 
Japan). The LC Solution v 1.25 software was used for system 
control. 
The chromatographic conditions established were: methanol-
water with 0.1% formic acid (20:80, v/v) was chosen as the 
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mobile phase, at flow rate 1.0 mL/min, photodiode array 
(PDA) detector set at 313 nm. The chromatographic column 
was a Phenomenex C18 Luna (250 x 4.6 mm, 5 μm) and C8 
guard column (4 x 3.0 mm; Phenomenex, USA) were kept at 
30 °C and the injection volume was 20 μL. 
Method Validation 
The chromatographic method developed by MTZ in 
biotransformation assay was validated to certificate the 
analytical method is singular and trustworthy. The 
chromatographic method was validated by evaluation of the 
analytical parameters including specificity, linearity, 
precision, and accuracy, stability and sensitivity in 
accordance with FDA – Bioanalytical method validation  
(18). The recovery, in this study, were not performed. 
Specificity 
For the specificity evaluation, the method was performed 
according to the chromatographic conditions described. The 
chromatograms of BIO, DC, and GC were compared to sterile 
culture (B) and corroborate to the absence of any interference 
in MTZ peak. 
Linearity 
A calibration standard curve was obtained through analysis of 
solutions obtained by spiking aliquots of Czapek-Dox 
medium with standard solutions of MTZ concentrations (10 - 
70 μg/mL, n = 3, for each concentration). The calibration 
curve was evaluated using least-squares linear regression 
analysis method and ANOVA (analysis of variance) 
statistical evaluation. The Lower Limit of Quantification 
(LLOQ) and Limits of Detection (LOD) were estimated 
according to the standard curve and confirmed through 
experiments. The reproducibility of the method was analyzed 
by replicates measurements using the assay.  
Precision and Accuracy 
The accuracy and precision of the method were determined 
by intraday and inter-day (n = 3, for each concentration) 
assays using Czapek-Dox medium samples spiked with MTZ 
(10, 40, and 70 μg/mL). Precision was expressed as the 
relative standard deviation (RSD%) and the accuracy was 
expressed as the percent ratio between the experimental 
concentration and the nominal concentration for each sample.   
Stability 
Stability of metronidazole tests was performed in three 
different ways: (1) freeze and thaw cycle stability and (2) 
stability at room temperature for 12 h. During freeze and thaw 
cycle stability, short-term room temperature stability was 
determined. To perform the freeze and thaw cycle stability, 
three aliquots of samples, prepared in Czapek-Dox culture 
medium at the concentration of 70 μg/mL of MTZ were 
stored at 5 °C for 24 h and thawed at room temperature. Then, 
the samples were refrozen for 12 h under the same conditions. 
The freeze and thaw cycle were repeated another two times 
and samples analyzed after the third cycle. For the 
determination of the stability at room temperature for 12 h, 
aliquots of samples prepared in Czapek-Dox culture medium 
at the concentrations specified previously were kept at 22 − 
25 °C. The concentration obtained from stability tests were 
compared with recovery concentration determined by freshly 
prepared samples being considered stable if the deviations 
(expressed as RSD, %) observed for the concentrations from 
the fresh samples were within < 15%.  The method was 
validated according to recommendations of the official guide 
(18).  
Results and discussion 
Fungal biotransformation study 
In general, drug metabolism studies use animal models, such 
as mice, dogs, and cats (1,19). Those methods suffer from 
limitations due to the ethical issues, species variation, and 
cost of experimental animals. Instead of animal models, in 
vitro and ex vivo studies have been chosen. For this reason, 
biotransformation using microbial have been explored to the 
development and drug discovery. The microbial, especially 
filamentous fungi, in biotransformation studies, represent an 
alternative to mimic mammalian metabolism (12,20).  
The work here presented as a part of our ongoing efforts 
focused on the development and optimization of 
biotransformation of drug studies and e validation of the 
analytical method.  In previous studies, several parameters 
related to the culture medium were modified during the 
process of biotransformation of drugs, such as the amount of 
oxygen, pH, temperature, and speed of culture medium 
shacking (21,22). According to those parameters, 
modifications were done to optimize de biotransformation 
process. As results, the better condition was defined, for 
metronidazole biotransformation, was to maintain the shaken 
condition at 120 rpm, room temperature at 27 °C and Czapek-
Dox as culture medium.   
For monitoring of biotransformation reactions, aliquots were 
collected every 24 hours, filtered and kept freeze until the 
analysis by the liquid chromatography method. After 8 days, 
the HPLC elution profiles of the samples was observed the 
MTZ biotransformation process showed the production of 
four products (The most polar substance was eluted in 2.6 
minutes, followed by 4.05, 4.60 and 5.20 minutes before then 
the MTZ, 5.65 minutes (Figure 2). The concentration of MTZ 
in BIO showed a decrease and, moreover, area peaks of 
metabolites were increasing during the time assay. Otherwise, 
the DC concentrations of MTZ had been maintained as the 
initial time and no different peak chromatographic was 
observed in the DC. According to this, is possible to infer the 
metronidazole was metabolized by C. elegans ATCC 9245. 
According to the results, the biotransformation reactions of 
metronidazole by C. elegans ATCC 9245 was effective. 
Those results are consistent with the hypothesis that C. 
elegans can mimic mammalian metabolism of drugs. In fact, 
this fungus has enzymes that can catalyze this reaction 
(12,23). Demonstrating the importance and necessity of 
investment in these studies involving filamentous 
microorganisms. According to the results of  DC, is possible 
to exclude the drug degradation in Czapek-Dox medium even 
though it was verified in the bioanalytical validation study 
Figure 3.  
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Figure 2 Comparatives chromatograms of metronidazole biotransformation study: A) Standard solution of MTZ (70 
μg/mL), B) Growth Control, C) Drug Control, D) Biotransformation and E) Blank. Both samples were incubated for 8 days. 
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Method Validation 
Analytical conditions allowed an adequate peak signal of 
MTZ (6.03 minutes) in the presence of matrix and fungi. 
Considering the possibility of secondary metabolites and the 
constituents of the culture medium, a selectivity test was run. 
However, it was not noted interference peaks into the 
chromatogram to the analyte and standard. 
The linearity of the method was verified by linear regression 
of the plot of the standard area versus the nominal 
concentrations of the MTZ. The method was linear over the 
concentration range of 10–70 μg./mL (y = 33129x - 3597.4, r 
= 0,999953).  According to data obtained from ANOVA, it is 
possible to ensure significant linear regression (Fcalculated = 
105741.3269 > Fcritical = 6.61) without deviation from linearity 
(r2 = 0.9941). Limits of detection and lower quantification 
(LOD and LLOQ) were 0.06 and 0.21 μg/mL, respectively.  
The precision and accuracy of the method were evaluated in 
terms of MTZ in the culture medium. These results show that 
the method is precise and accurate within limits appropriate 
for analytical validation. 
 
Table 1 Calibration curve for the analytical method for 
metronidazole quantification in Czapek-Dox medium in the range of 
10.0 μg/mL to 70 μg/mL. 
 
Additionally, the stability at room temperature for 12 h of 
MTZ in Czapek-Dox medium showed RSDs lower than 15%, 
in this condition MTZ shown to be stable. 
Conclusions 
The validation of the bioanalytical method for metronidazole 
ensured the reliability and credibility of the method 
developed in this study. The results presented in this study 
contribute to increasing the knowledge of biotransformation 
mediated by C. elegans ATCC 9245 of drugs in a class little 
explored. Furthermore, the analytical results of the negative 
control exclude possible degradation of the drug in the 
aqueous medium. The validation of the bioanalytical method 
for metronidazole ensured the reliability and credibility of the 
bioanalytical method developed in this study, according to 
normative guides of bioanalytical validation (18,24). 
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